CAR-equipped CD8+ T cells targeting tumor-specific antigens or neoantigens have thus far shown great potential in combating certain hematological malignancies by targeting cell-surface proteins that are ubiquitously expressed on tumor cells, such as CD19 [49,50]. This evidence concerns the gene CD8A and neoplasm.